Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Trial ID or NCT#
NCT02303041
Status
NOT RECRUITING
Purpose
This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Official Title
An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Investigator(s)
Anne Lynn S. Chang, MD
Dermatologist,
General dermatologist,
Dermatologic oncologist,
Cutaneous oncology specialist
Professor of Dermatology
Anthony Oro, MD, PhD
Dermatologist,
Hair loss specialist,
Dermatologic oncologist,
Cutaneous oncology specialist,
Skin stem cell specialist
Eugene and Gloria Bauer Professor
A. Dimitrios Colevas, MD
Medical oncologist,
Head and neck specialist,
Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Contact us to find out if this trial is right for you.
Contact
CCTO Office
View on ClinicalTrials.gov
